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ABSTRACT Significant iatrogenic bleeding during flexible bronchoscopy is fortunately rare and usually
self-limiting. Life-threatening bleeding, however, can occur, especially after conventional or cryoprobe-
assisted transbronchial biopsy. The aim of this review is to provide the practising pulmonologist with a
concise overview of the incidence, severity and risk factors for bleeding, to provide sensible advice on
prophylactic measures and to suggest a plan of action in the case of significant bleeding. Bronchoscopy
units should have a standardised approach and plan of action in the case of life-threatening haemorrhage.
Wedging the bronchoscope in the bleeding segment, turning the patient in an anti-Trendelenburg position
and onto the side in order for the bleeding lung to be in the dependent position, installing
vasoconstrictors and using a tamponade balloon early are the recommended first-line strategies. Involving
a resuscitation team should be considered early in the case of massive bleeding, desaturation and
haemodynamic instability.
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Introduction
Flexible bronchoscopy (FB) is one of the most commonly performed procedures by chest physicians.
Iatrogenic bleeding, although rarely reported [1], is by far one of the most frightening situations
encountered in daily practice [2]. Despite the fact that this complication may potentially be
life-threatening [3, 4], the guidelines of the main thoracic societies on FB provide few recommendations
on the management of iatrogenic bleeding [5]. The aim of this review is to provide the practising
pulmonologist with a concise overview of the incidence, severity and risk factors for bleeding, to provide
sensible advice on prophylactic measures and to suggest a plan of action in the case of significant bleeding.
References for this review were identified through searches of PubMed for articles published on this topic.
Articles resulting from these searches and relevant references cited in those articles were reviewed.
Incidence and severity of bleeding
Bleeding during diagnostic FB occurs in between 0.26% and 5% of cases depending on the definition, the
patient population and the procedures performed [1, 6–8]. Transbronchial lung biopsies (TBLBs) increase
the risk of bleeding significantly. Massive bleeding and mortality are exceedingly rare, and are
predominantly induced by therapeutic rather than diagnostic bronchoscopies (incidence 0.059% versus
0.031% and 0.012% versus 0.003%, respectively) [3]. However, all endoscopy centres, and particularly
high-volume endoscopy units, may experience near-fatal or fatal bleeding during everyday practice [3].
The severity of bleeding has been characterised according to the volume of blood and fluid aspirated [1] or
according to the intervention needed in order to control the bleeding [8]. The latter is less influenced by
measurement variability and blood dilution with bronchial secretions and instilled substances [2], and so
is more appropriate for describing clinically relevant bleeding. Moderate and severe bleeding (i.e. clinically
significant bleeding) are defined as bleeding requiring wedging of the biopsied segment with the
bronchoscope and as bleeding needing additional interventions (placement of a temporary
bronchus-blocker, application of a fibrin sealant, admission to a critical care unit or the need for blood
products), respectively [8].
Risk factors
Several factors have been reported to influence the risk of bleeding during FB, which can arbitrarily be
divided into procedural related, patient related, haemostatic risk factors and related to the tissue sampled
(figure 1). The risk of bleeding is expected to rise in the presence of multiple risk factors.
Risk factors related to the endoscopic procedure
Bleeding risk differs depending on the procedure performed and the vascularisation of the tissue sampled.
The estimated risk for different procedures, inferred from the available literature and pulmonologists’
appraisal [9], is summarised in figure 1. Inspection and bronchoalveolar lavage (BAL) are considered very
atraumatic and have been reported to be safe, even via the transnasal route in severely thrombocytopenic
patients [10, 11]. Many authorities, however, recommend oral flexible bronchoscope insertion in
thrombocytopenic patients. Endobronchial ultrasound-guided transbronchial needle aspiration
(EBUS-TBNA) is a very safe procedure, with bleeding occurring in only 3 out of 1317 patients undergoing
the procedure [12, 13]. In the same study, TBLB was the only factor associated with complications [13].
EBUS-TBNA may even be safe in patients taking clopidogrel [14]. In general, brushing and TBNA of
peripheral and endobronchial lesions are very safe. Significant bleeding may occur after sampling of a very
well vascularised tumour (e.g. carcinoid tumours) or after endobronchial biopsy of an endobronchial tumour
(bleeding from a central lesion). Transbronchial biopsies of peripheral lesions or lung parenchyma (bleeding
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FIGURE 1 a) Factors influencing the risk of bleeding. b) Risk of bleeding for different procedures. Risk of
bleeding is given as an estimated risk inferred from the available literature and according to the authors’
experience. BAL: bronchoalveolar lavage; EBB: endobronchial biopsy; EBUS: endobronchial ultrasound;
TBNA: transbronchial needle aspiration; TBLB: transbronchial lung biopsy.
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from the periphery) are associated with the highest risk of clinically significant bleeding [1, 7, 15]. In
fact, clinically moderate to severe bleeding was reported in about 1.1–2.8% of patients undergoing
TBLB [1, 8, 16]. The highest risk of bleeding has been reported after cryobiopsies of lung parenchyma,
which has recently been suggested as a technique allowing a higher diagnostic performance in interstitial
lung disease [17–19]. This technique allows much larger biopsies than conventional TBLB, at the price of
a trend towards a higher frequency of significant bleeding [19–21], motivating the preventive use of a
tamponade balloon, which is inflated at the moment of biopsy [19]. An occlusion balloon is commonly
introduced via the endotracheal tube and placed at the entrance to the lung segment from which the
transbronchial lung biopsy is to be obtained, and inflated just after biopsy [21].
Patient-related risk factors
Several patient characteristics have been reported to influence the risk of bleeding during a diagnostic FB.
Lung malignancy is a common indication for FB and has been consistently reported as a considerable risk
factor for bleeding [1]. Immunocompromised patients [22], and especially lung transplant (LTX)
recipients, are more likely to have new or worsened haemoptysis and to have the procedure terminated
early for bleeding [23]. However, no specific risk factors for bleeding in LTX recipients could be found [24].
FB and tissue sampling in patients presenting a superior vena cava syndrome has been reported to be
safe [25]. Pulmonary hypertension (PH) could, at least theoretically, lead to excessive bleeding following
TBLB, and current recommendations [5] suggest that TBLB should be performed with caution in patients
with elevated pulmonary arterial pressure (PAP) [5]. Furthermore, a survey has reported that most
pulmonologists consider a mean PAP (mPAP) greater than 40 mmHg as unsafe for TBLB [26]. In a
prospective controlled trial in patients with PH from different aetiologies, 24 patients with a mean mPAP
of 45 mmHg underwent transbronchial biopsy. Even patients with severe PH experienced no significant
bleeding or worsening hypoxaemia, suggesting that FB can be performed safely in patients with mild to
moderate PH [27].
Patients with lung malignancy often have a procoagulatory state that may promote the development of
venous thrombosis and lung embolism. It is therefore quite common to have to perform a bronchoscopy
in a patient with a lung mass and a lung embolism. In haemodynamically stable and non-hypoxaemic
patients, bronchoscopy and tissue sampling may be performed after withholding the anticoagulation
therapy, but is considered a situation at high risk of bleeding and thrombotic complication (especially in
the first 3 months of anticoagulation). In this situation, it is common practice to switch to
low-molecular-weight heparin (LMWH) or unfractionated heparin (UFH) and omit subcutaneous LMWH
the day of the procedure [5] or stop intravenously UFH 6 h before the procedure [5]. The anticoagulation
is restarted 4 h after the procedure in the absence of bleeding.
Haemostasis-related risk factors
The goal of performing coagulation studies is to unmask disorders that could increase the risk of
iatrogenic bleeding. However, the prevalence of inherited coagulopathies is low and, in patients with the
most common disorder (von Willebrand’s disease), the results of routine coagulation tests may be normal.
Similarly to coagulation studies in patients undergoing elective surgery [28], coagulation tests before FB
with transbronchial biopsy were not showed to predict bleeding [29–31]. Furthermore, animal data on a
small number of anticoagulated pigs showed no bleeding [32], supporting the belief that life-threatening
bleeding often results from the unpredictable biopsy of a sizeable pulmonary or bronchial artery [4].
Considering the paucity of data, the British Thoracic Society (BTS) recommends performing coagulation
studies, a platelet count and haemoglobin concentration when there are clinical risk factors for abnormal
coagulation (low level of evidence/grade D).
BAL can be performed with platelet counts greater than 20000 per μL (Grade D) [5]. Although not
supported by published data, BAL is safely performed even in patients receiving a therapeutic
anticoagulation or double antiplatelet treatment.
Uraemia affects platelet function and prolongs bleeding time. There is a paucity of data on the safety of FB
in uraemic patients. An increased risk of bleeding with TBLB [1, 22] could not be documented in a recent
retrospective study [33]. Patients on chronic haemodialysis received haemodialysis and desmopressin
intravenously before the procedure, and some authors suggest this approach [34]. Most pulmonologists,
however, do not consider a high creatinine value as a contraindication to perform TBLB, and only 37% of
them consider it appropriate to administer desmopressin prior to TBLB in uraemic patients [26]. Liver
insufficiency and failure may induce coagulation abnormalities (thrombin time prolongation and
thrombocytopenia), which may become clinically significant. In the suspicion, or evidence, of liver disease,
we suggest performing coagulation studies and to optimise the coagulation status prior to bronchoscopy.
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A large number of drugs inhibiting platelet function or coagulation, with very different pharmacodynamic
and pharmacokinetic properties, are registered for several indications and many more are released every
year. Inevitably, these drugs raise the risk of iatrogenic bleeding, and the indication for tissue sampling as
well as the risk and effectiveness of withholding antithrombotic treatment should be discussed on a
case-by-case basis, considering and balancing the risk of thrombotic complications and the potential
benefit from tissue sampling. The discontinuation of or alternatives to anticoagulation or antiplatelet
therapy should be evaluated and discussed carefully with the treating cardiologist, neurologist or
angiologist. For a few of these drugs, well-designed studies have shown their influence on iatrogenic
bleeding risk during bronchoscopy [8, 35]. Although, for many antithrombotic drugs (e.g. ticagrelor,
prasugrel, rivaroxaban and apixaban), no data are available specifically for bronchoscopy, the potential risk
of bleeding may be extrapolated from the incidence of major bleeding reported in registry trials [36, 37].
Acetylsalicylic acid has been shown not to increase the risk of bleeding in patients undergoing TBLB [8],
while clopidogrel has been associated with a significant increase in the frequency of clinically significant
bleeding after TBLB [35]. In fact, this landmark trial was prematurely stopped because of an excessively
high rate of bleeding in the clopidogrel group. An unpublished trial including only 15 patients and
EBUS-TBNA of 40 lymph nodes showed a low risk of bleeding in patients taking clopidogrel [14].
Considering the pharmacokinetic properties of clopidogrel, we suggest withholding the drug for 7–10 days
before performing TBLB and other invasive procedures. Prasugrel [38] and ticagrelor are newly developed
adenosine diphosphate (ADP) receptor antagonists that induce higher and more consistent levels of
platelet inhibition than clopidogrel [39]. These drugs have been associated with an increased rate of
spontaneous major bleeding and should therefore be withheld before performing invasive bronchoscopic
interventions.
Patients receiving therapeutic anticoagulation
For patients under therapeutic anticoagulation with LMWHs or direct antithrombin inhibitors, and in
whom this treatment may be withheld for a short period of time, the suggested time prior to FB and tissue
sampling is reported in table 1. As previously mentioned, as the risk of a thromboembolic event (TE)
increases, it is critical to minimise or discontinue anticoagulation therapy for as short a period as possible.
The recommendation to perform a periprocedural intravenous UFH or subcutaneous LMWH bridging
therapy depends on the risk of TE: it is not necessary in low-risk situations, but it can be considered in
intermediate-risk situations and should be administered in high-risk scenarios [5, 40]. For most patients
presenting a low to intermediate risk of TE (no mechanical heart valve; absence of stroke or systemic
embolism within the previous 12 weeks; cardioembolic risk score (CHADS2) <5 points) stopping warfarin
5 days prior to bronchoscopy and resuming it the evening after the procedure is the approach of choice [5]
and is not associated with an increased risk of TE [41].
For patients at high risk for a thrombotic complication (e.g. patients with a recent pulmonary embolism),
it is preferable to perform bronchoscopy and tissue sampling at least 3 months after the PE or perform the
tissue sampling with a periprocedural UFH or LMWH bridging therapy (as described above).
Risk factors related to the tissue sampled
The vascularisation of the tissue sampled is a significant risk factor for bleeding. Biopsies of
hypervascularised inflammatory tissue, tumours or metastasis are associated with a higher rate of clinically
significant bleeding. Several publications have reported a higher frequency of severe bleeding after
endoscopic biopsy of carcinoids [42]. DIXON et al. [42] reported a retrospective analysis of all
bronchopulmonary carcinoid tumours referred to a tertiary-care facility over one decade. Thirty patients
underwent bronchoscopy for diagnostic evaluation, and only two complications of moderate to severe
bleeding occurred, with no emergent thoracotomies, transfusions or deaths. Endobronchial metastasis of
renal cancers or thyroid cancers, amyloidosis or bronchial anthracosis are also more prone to severe
haemorrhage.
Furthermore, a situation associated with a very high risk for severe bleeding is the presence of vascular
abnormalities. Biopsy of hypertrophic dysplastic arteries running in the bronchial submucosa, which may
appear as a non-pulsating endobronchial lesion, vascular abnormalities in patients with bronchiectasis or
pulmonary artery pseudoaneurysm induced by endobronchial brachytherapy may causes massive
iatrogenic bleeding [43, 44].
Prophylactic measures
The indication for flexible bronchoscopy and sampling procedures as well as the potential risks and
benefits should always be carefully evaluated. In particular, the necessity to perform TBLB must be
dictated by potentially important clinical implications. Resuscitation equipment and additional staff
necessary for emergency resuscitation should be readily available should an unexpected life-threatening
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complication such as massive bleeding occur. Potentially correctable risk factors (figure 1) should be
identified and optimised prior to performing FB [5].
For bronchoscopy through the nares, phenylephrine 0.5% or xylometazoline 0.1% can be helpful in
vasoconstricting the mucosa of the nares and allowing easier passage of the scope.
The role of the prophylactic instillation of vasoconstrictors in the airways, mostly adrenaline (epinephrine)
or terlipressin, is not well studied. The BTS recommend prophylactic instillation if bleeding is likely [5].
Adverse cardiac events, however, can occur at doses as low as 100 μg of adrenaline [45], and the effects of
adrenaline in the airways may be unpredictable. The instillation of vasoconstrictors is widely
recommended for well-vascularised endobronchial tumours (bleeding from a central lesion). No data are
available about the value of this practice before TBLB of peripheral lung lesions or in diffuse parenchymal
lung disease (bleeding from the periphery). In cases at high risk for bleeding, the use of a bronchoscope
with a large working channel should be considered.
TBLB is the procedure most commonly associated with complications, and life-threatening bleeding often
results from the unpredictable biopsy of a sizeable pulmonary or bronchial artery [4]. TBLBs may be
performed for a localised peripheral lesion or diffuse parenchymal pulmonary disease. In the latter,
sampling of dependent segments may facilitate self-tamponade as well as limit inundation of the bronchial
tree in the case of bleeding, helping to maintain visualisation. In fact, further visualisation is crucial in
order to apply endobronchial therapies directed to stop the bleeding. Two different TBLBs techniques have
been described. The most commonly recommended [5] techniques are 1) to wedge the bronchoscope into
TABLE 1 Suggested cutoff values for several parameters and time interval for the interruption of different drugs prior to the
most commonly performed procedures during flexible bronchoscopy
Procedure Resume therapy
afterBAL EBB/TBNA/
EBUS-TBNA
TBLB
Patient-related risk factors and
contraindications
Pulmonary hypertension No No sPAP >50 mmHg or mPAP
>30 mmHg
Vena cava syndrome No Relative contraindication
Haemostasis-related risk factors and
contraindications
Platelets ×109 per L <20000 <75000
INR/PT No >1.4 or <60%
Drugs
Heparins
UFH prophylactic dose No 6-h interval period Same day
UFH therapeutic dose No 6-h interval period 4–12 h
LWMH prophylactic dose No 10–12-h interval period Same day
LWMH therapeutic dose# No 24-h interval period 4–12 h
Fondaparinux No 36–42-h interval period 4–12 h
Platelet-aggregation inhibitors
Acetylsalicylic acid No Do not stop Not stopped
Clopidogrel No 5–7 days 4–12 h
Ticagrelor No 5 days 4–12 h
Prasugrel No 7–10 days 4–12 h
Oral anticoagulants¶
4-hydroxycoumarin No 5 days 4–12 h
Acenocoumarol No 3 days 4–12 h
Phenprocoumone No 8 days 4–12 h
Oral anticoagulants+
Dabigatran§ No 3 days 4–12 h
Rivaroxaban No 2 days 4–12 h
Apixaban§ No 2 days 4–12 h
BAL: bronchoalveolar lavage; EBB: endobronchial biopsy; TBNA: transbronchial needle aspiration; EBUS: endobronchial ultrasound; TBLB:
transbronchial lung biopsy; INR: international normalised ratio; PT: prothrombin time; UFH: unfractionated heparin; LMWH: low molecular
weight heparin; sPAP: systolic pulmonary arterial pressure; mPAP: mean pulmonary arterial pressure. #: normal renal function; ¶: coumadine;
+: direct thrombin inhibitor and direct factor Xa inhibitor; §: creatinine clearance >30 mL·min−1.
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the target airway during and after the biopsy until haemostasis is achieved, avoiding suctioning in order to
allow clot stabilisation [46], or 2) without wedging the bronchoscope, suction with the “back-and-forth
technique” in the case of bleeding until bleeding stops [24]. These two techniques have not been
compared regarding the frequency and efficacy of bleeding control.
Plan of action in the case of bleeding
General considerations
Significant iatrogenic endobronchial bleeding is rare and mostly stops without further intervention.
However, serious bleeding occasionally occurs and may be associated with significant morbidity. It is
suggested that every bronchoscopy unit should have a standard operating procedure (SOP) or action plan
in case of significant bleeding in order to optimise care and reduce morbidity.
When bleeding occurs, it is paramount to differentiate between a limited, self-controlled bleed and
clinically significant bleeding requiring intervention. In fact, the signs and features of clinically significant
and potentially life-threatening bleeding should prompt interventions or even the involvement of a
resuscitation team, as in the case of massive haemoptysis. Similarly to the definition of massive
haemoptysis [47], the term “life-threatening bleeding” may provide a more broad and informative
description of the risk and the kind of therapeutic response needed. The consequences of an iatrogenic
bleeding go beyond actual blood loss. The lung function and gas exchange prior to the intervention as well
as the ability to maintain the airways clear of blood, which is often reduced due to the concomitantly
administered sedation, are important factors to be considered.
Plan of action for life-threatening iatrogenic bleeding
Massive bleeding, persistent desaturation and haemodynamic instability should be viewed as warning signs
requiring the assistance of a resuscitation team (figure 2). The management strategies used in this case are
strongly dependent on local expertise. Experienced centres often favour an assertive approach with general
anaesthesia (including mechanical and the application of positive end-expiratory pressure (PEEP)), rigid
bronchoscopy and advanced haemostatic therapies that allow the rapid clearance of blood from the
inundated bronchial tree, isolation of the bleeding lung/lobe with ventilation/oxygenation of the other
non-bleeding lobes, and advanced haemostatic therapies for bleeding control. Advance haemostatic
therapies include argon plasma coagulation and laser coagulation of the central bleeding source, and
insertion of packing or blocking devices in the case of peripheral bleeding. However, rapid sequence
orotracheal intubation, mechanical positive pressure ventilation with the application of PEEP and
introduction of a bronchoscope with a large working channel scope and a haemostatic balloon next to it
are a valuable alternative. Further, selective intubation and exclusion of the bleeding lung can also be
considered. After stabilisation bronchial artery embolisation may be considered.
Plan of action for a non-life-threatening iatrogenic bleeding
In the case of non-hypoxaemic bleeding, we suggest differentiating it according to the source of bleeding,
as specific advanced manoeuvres for the control of bleeding differ slightly depending on the site of
bleeding; i.e. bleeding from a central endobronchial lesions (e.g. after an endobronchial biopsy of an
endobronchial tumour) versus bleeding from the lung periphery (e.g. after transbronchial biopsies of a
peripheral lesion or lung parenchyma).
Bleeding from the lung periphery
The plan of action for bleeding from the periphery (e.g. after transbronchial biopsy of lung tissue or
peripheral lesion) proposed in figure 2 has been developed by integrating the available literature, as well as
local experience and expertise. The recommended management approach has not been validated
prospectively and may not be applicable in all centres, because it is largely influenced by the technique
used to perform TBLB (wedging technique versus non-wedging technique), local expertise and available
resources. Despite these limitations, it represents the plan of action we consider the most appropriate.
Turning the patient onto the bleeding side and in an anti-Trendelenburg position should be the first
reaction in order to prevent and minimise inundation of the non-bleeding lung and guarantee adequate
oxygenation.
Even if it has never been compared in a trial assessing the frequency and risk of bleeding, the wedging
technique for TBLB [46] has the advantages of allowing endoluminal compression and blood stasis (which
promotes clot formation and haemostasis) without losing the position, which could be difficult to regain
in the case of diminished visibility. For these reasons, we consider this technique to be the technique of
choice and recommend applying suction only 2–3 min after the TBLB has been performed in order to
allow clot formation. Differently, continuous suction should be applied where visibility has been lost, in
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order to maintain airway clearance and visibility as well as regain the wedging position in the bleeding
segment/subsegment.
The instillation of ice-cold saline and the use of vasoconstrictors and procoagulants have been suggested to
promote haemostasis in the setting of endobronchial bleeding. There are limited reports, however,
describing clinical outcomes that can convincingly advocate for or against these procedures. Ice-cold 0.9%
saline instillation is often the first measure adopted, originating from the concept of cold-induced
vasoconstriction, which, similar to cutaneous vessels [48], could occur in pulmonary vessels after localised
cold exposure. Furthermore, the instillation of a certain volume of saline has the advantage of helping
cleaning the optic and regain visibility. Hypothermic inhibition of clot formation [49] is not expected to
play a significant role after repeated instillation of 5–10 mL of ice-cold saline.
The use of vasoconstrictors, especially as instillation, is also common practice in the case of iatrogenic
bleeding [5]. As pulmonary organogenesis occurs by branching morphogenesis, proximal administration
and absorption of vasoconstrictors may constrict the vessels feeding the injured vasculature, thus
decreasing flow and promoting haemostasis. However, the contribution to haemostasis made by
vasoconstrictors in patients with severe bleeding following TBLB is unknown, and no vasoconstrictor has
been reported to be more effective than another. Adrenaline has been, by far, the most exhaustively
studied and used substance. Despite that, the doses and dilutions of adrenaline suggested by textbooks,
publications and guidelines for management of airway bleeding during bronchoscopy vary widely from “small
amounts” of 1:100000 solution up to 20 mL of 1:20000 solution, thus leading to some confusion [50].
The BTS guidelines propose the instillation of 5–10 mL of 1:10000 adrenaline (500–1000 μg) [5]. Cardiac
arrhythmia after adrenaline instillation has been well known to be a complication since the 1970s [45],
Bronchoscope not
wedged Bronchoscope wedged
Reposition the patient in order to 
have the bleeding lung in the 
dependent position and the 
patient in anti-Trendelenburg 
position
Alert resuscitation team in 
case of:
  Massive bleeding
  Desaturation
  Haemodynamic instability
Do not remove the blood clot 
from the bleeding segment
Continue suction and
try to re-wedge
Maintain the wedging 
position for 3–5 min to 
allow clot formation
5–10 mL cold NaCl
0.9% instillation
Adrenaline# or
terlipressin¶ instillation
Suction to assess the 
severity of bleeding
Consider the use of 
tamponade balloon¶
Alert resuscitation team and initiate massive 
haemoptysis protocol
Consider intravenous
terlipressin (1 mg i.v. 
every 6 h)
FIGURE 2 Proposed plan of action in the case of iatrogenic bleeding during flexible bronchoscopy originating
from the periphery. #: adrenaline solution f.e. 1:25000=0.04 mg·mL−1=40 μg·mL−1. Maximum volume allowed
for instillation: 1 mL/10 kg body weight (e.g. 7 mL for 70 kg of body weight). ¶: terlipressin (glypressin)
0.2 mg·mL−1, e.g. 2 mL, to be repeated if needed.
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and adverse cardiac events can occur at doses as low as 100 μg. Limited data are available on the systemic
absorption and effects of endobronchially administered adrenaline. In patients undergoing elective hip
surgery 0.5 μg·kg−1endotracheal adrenaline had no haemodynamic effects [51]. Recently, potentially fatal
arrhythmia occurred after the instillation of 5 mL of 1:20000 diluted adrenaline (200 μg) via the guide
sheath of a radial probe endobronchial ultrasound (R-EBUS) in two patients developing iatrogenic
bleeding after TBLB [52], suggesting that the site of instillation may play a role. This theory is supported
by a pharmacokinetic study in a canine model that demonstrated a more than fourfold increase in plasma
levels when adrenaline was directly administered into the distal versus the proximal airways [53]. The
antidiuretic hormone (ADH or vasopressin) analogues terlipressin (also called glypressin) and ornipressin
have potent effects on plasma osmolality, volume and vascular tone acting on V1, V2, V3 and
oxytocin-type receptors (OTRs). V1 receptors are found on vascular smooth muscle of the systemic,
splanchnic, renal and coronary circulations. The haemostatic effect of ADH analogues is most likely due to
the potent bronchial artery vasoconstriction combined with vasopressin-induced pulmonary vasodilation [54].
Intravenous application of terlipressin in doses typically administered for oesophageal variceal bleeding
(2 mg/4 h) [55] has been shown to stop or significantly reduce the bleeding in patients with severe
haemoptysis of different origins [56]. Furthermore, the instillation of 0.5 mg terlipressin in the airways has
been associated with bleeding stop and minor haemodynamic changes in a retrospective study comparing
terlipressin to ornipressin in patients developing biopsy-associated bleeding [57]. Even if the plasma
level after intravenous terlipressin administration was 251-fold higher than after endobronchial
administration, the bronchial mucosa pallor appeared earlier after topical than after intravenous
terlipressin application [58]. Unfortunately, terlipressin in combination or versus adrenaline has never been
studied. As reported in table 2, after the instillation of adrenaline and in the case of bleeding persistence,
and as a temporary measure awaiting the intervention of the resuscitation team and the interventional
pulmonologist, we propose considering the administration of intravenous terlipressin.
Tranexamic acid (TXA) is an antifibrinolytic agent that acts by binding to plasminogen and blocking the
interaction of plasminogen with fibrin, thereby preventing dissolution of the fibrin clot [59]. The very
encouraging results of the CRASH-2 trial showing a significant mortality reduction in bleeding adult
trauma patients [60] suggested the administration of this drug for other bleeding situations. The rationale
behind the positive effect of TXA in bleeding trauma patients is that the stimulation of fibrinolysis due to
trauma may become pathological (hyper-fibrinolysis) and promote bleeding [61]. In a pilot not-controlled
study including iatrogenic and non-iatrogenic endobronchial bleeding, the instillation of TXA was shown
to be a promising technique, especially for iatrogenic bleeding [62]. Other case studies revealed similar
results [63, 64]. However, thrombotic complications after the administration of TXA have been reported.
Considering the lack of evidence regarding TXA administration for endobronchial bleeding and the
potentially serious side events (thrombotic complications), we do not recommend its use in this situation
[65, 66].
Fibrin sealant, also called fibrin glue, is a two-component system in which a solution of concentrated
fibrinogen and factor XIII is combined with a solution of thrombin and calcium in order to form a
coagulum, simulating the final stage of the clotting cascade. It is mostly applied as liquid glue or a sealant
patch in the case of surgery-induced bleeding. Several case reports have described the successful instillation
of fibrin sealant for persistent severe haemoptysis [67–69], without any complications.
TABLE 2 Summary of level of evidence and grade of recommendation as suggested in the British Thoracic Society guidelines [5]
Procedure Level of
evidence
Grade of
recommendation
Ref.
Perform coagulation studies, platelet count and haemoglobin concentration when there
are clinical risk factors for abnormal coagulation
3 D [5]
Degree of bleeding is higher after TBLB than EBB 3 [1]
LTX recipiens are more likely to bleed after TBLBs (not explained by clotting values or
aspirin use)
3 [24]
Inspection and BAL can be performed in severely thrombocytopenic patients (platelet
>20000×109 per L−1)
3 D [10]
Acetylsalicylic acid has not been shown to increase the risk of TBLB-related bleeding C [8]
Clopidogrel has been associated with a significant increase in the frequency of clinically
significant bleeding after TBLB
2 C [35]
TBLB: transbronchial lung biopsy; EBB: endobronchial biopsy; LTX: lung transplant; BAL: bronchoalveolar lavage.
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Furthermore, the use of different types of tamponade balloons has been described (figure 3). Fogarty
balloons (Fogarty Occlusion Catheter; Edwards Lifesciences, Irvine, CA, USA) may have the advantage of
being universally available and exist in a wide range of sizes. Specifically developed tamponade balloons are
double-lumen, bronchus-blocking catheters that can be introduced through the working channel of a
standard flexible bronchoscope to be placed into the bleeding bronchial segment. Moreover, the internal
lumen allows the instillation of substances improving haemostasis. The successful use of this balloon has
been reported in 26 patients with moderate to severe bleeding due to different conditions [70]. Balloons
were placed in the lobar or segmental bronchi and left up, usually between a few hours and 2–3 days (up to
7 days), allowing stabilisation and a complementary treatment (surgery, radiation or bronchial arterial
embolisation). Larger balloons with larger catheters may be introduced through an endobronchial tube next
to the scope and block a main bronchus, staying in place via a three-way port after the scope is retracted.
Bleeding from a central lesion
The principles of bleeding management originating from a central lesion do not differ significantly from
that applied in a bleeding originating from a peripheral lesion. Similarly, a haemostatic balloon may be
used to encourage local coagulation. However, with a visible central source of bleeding, the opportunity for
targeted coagulation should be considered. Argon plasma coagulation (APC) is a noncontact thermal
ablation technique that uses argon gas to generate heat, which, in turn, can be used to achieve haemostasis
[71, 72]. Thermal energy is delivered with a depth of penetration of roughly 2–3 mm, producing tissue
coagulation and destruction. Due to these features, APC is a useful modality for the treatment of
superficial/flat lesions, as well as those that are highly vascular or bleeding. Its advantages include its ease
of application and safety due to its reduced depth of penetration and lower cost compared to laser
techniques. The plasma jet also improves visualisation of the bleeding lesion due to the clearing effect of
the gas jet. Laser coagulation therapies (mostly Nd:YAP or diode lasers) are other valuable possibilities that
allow deeper coagulation. However, laser coagulation should be performed by an experienced
interventional bronchoscopist due to the deeper penetration and risk of complications [73]. Furthermore,
monopolar electrocautery can be used for contact diathermy coagulation.
In conclusion, significant iatrogenic bleeding during FB is rare and usually self-limiting. Life-threatening
bleeding may occur, especially after conventional or cryoprobe-assisted TBLB. Bronchoscopy units should
have a standardised approach and plan of action in case of life-threatening haemorrhage, including the
involvement of a resuscitation team. Wedging the bronchoscope in the bleeding segment, instillations of
vasoconstrictors and the early use of a tamponade balloon are the recommended first-line strategies.
a)
b)
c)
FIGURE 3 Different types of haemostatic balloon catheters. a) Decomposable haemostatic endoscopic balloon
catheter (size 6 French (2 mm), minimum working channel size 2.4 mm) allowing placement of the catheter
through the working channel and removal of the bronchoscope without removal of the catheter (Rüsch
Bronchus Blocker; Teleflex Medical, Kernen, Germany). b) Haemostatic endoscopic balloon catheter (size 4
French (1.4 mm), minimum working channel size 2 mm, maximal diameter of the inflated balloon 11 mm) for
blocking lobar or segmental bronchi (haemostatic balloon catheter; Olympus, Tokyo, Japan). The blockage of
a main bronchus can be achieved with the larger Arndt and Cohen endobronchial blockers (7–9 French, Cook
Medical, Bloomington, IN, USA). c) Fogarty arterial embolectomy catheter (size 4 French (1.35 mm), minimum
working channel size 2 mm). Fogarty catheters are available in sizes ranging from 2 to 8 French.
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